Related Experiment Videos
Pharmacokinetics of teicoplanin in children
Insights
This study assessed teicoplanin pharmacokinetics in pediatric and neonatal populations. Teicoplanin demonstrated excellent tolerability and supported dosage recommendations for these patient groups.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Neonatal Care
Background:
- Teicoplanin is an important antibiotic for treating Gram-positive bacterial infections.
- Understanding teicoplanin pharmacokinetics in pediatric and neonatal populations is crucial for optimizing treatment efficacy and safety.
Purpose of the Study:
- To evaluate the pharmacokinetic profile of teicoplanin in children and neonates.
- To establish safe and effective dosage recommendations for teicoplanin in these age groups.
Main Methods:
- A single dose of 6 mg/kg teicoplanin was administered to children and neonates.
- Serum and urine samples were collected over ten days for teicoplanin concentration analysis using high-performance liquid chromatography.
- Pharmacokinetic parameters were determined using an open two-compartment model.
Main Results:
- Teicoplanin exhibited excellent tolerability in both children and neonates.
- Mean Cmax was 48.6 mg/l in children and 19.6 mg/l in neonates.
- Mean half-life (t1/2 beta) was 20.5 hours in children and 30.3 hours in neonates.
Conclusions:
- Teicoplanin pharmacokinetic parameters differ between children and neonates.
- The study provides a basis for developing evidence-based teicoplanin dosage recommendations for pediatric and neonatal patients.
Abstract:
A single dose of 6 mg/kg teicoplanin was infused over 10 min in six children of mean age 7 years, and a single dose of 6 mg/kg was infused over 20 min in four neonates of mean age 8.5 days. Serum sampling was performed at 0 and 10 min and at 1, 4, 12 and 24 h and thereafter 24-hourly, up to ten days. Urine was collected for each 24 h throughout the study in children. Teicoplanin was assayed by high performance liquid chromatography. Tolerability of teicoplanin was excellent both in children and in neonates. For all the patients the serum concentrations of teicoplanin followed an open two-compartment model. Mean Cmax was 48.6 +/- 16.7 mg/l (10 min) in children, and 19.6 +/- 1.05 mg/l (20 min) in neonates, and mean t1/2 beta was 20.5 +/- 5.5 h and 30.3 +/- 6.3 h, respectively. On the basis of the results dosage recommendations for children and neonates are made.